Evidence map›Paper›PMID 38748042›Full record

ArticleEJNMMI reports2024

Efficacy and safety of FDG-PET for determining target volume during intensity-modulated radiotherapy for head and neck cancer involving the oral level.

Yasuo Kosugi, Keisuke Sasai, Naoya Murakami, Tatsuki Karino, Yoichi Muramoto, Terufumi Kawamoto, Masaki Oshima, Noriyuki Okonogi, Jun Takatsu, Kotaro Iijima and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yasuo KosugiDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Keisuke SasaiDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Naoya MurakamiDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. n.murakami.zi@juntendo.ac.jp.ORCID http://orcid.org/0000-0003-0660-9987
Tatsuki KarinoDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Yoichi MuramotoDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Terufumi KawamotoDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Masaki OshimaDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Noriyuki OkonogiDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Jun TakatsuDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Kotaro IijimaDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Shuhei KarubeDepartment of Radiology, Juntendo University Hospital, Tokyo, Japan.
Akira IsobeDepartment of Radiology, Juntendo University Hospital, Tokyo, Japan.
Naoya HaraDepartment of Radiology, Juntendo University Hospital, Tokyo, Japan.
Mitsuhisa FujimakiDepartment of Otorhinolaryngology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Shinichi OhbaDepartment of Otorhinolaryngology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Fumihiko MatsumotoDepartment of Otorhinolaryngology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Koji MurakamiDepartment of Radiology, Juntendo University, Tokyo, Japan.
Naoto ShikamaDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Funding

Grant-in-Aid for Scientific Research 22K07779
6 · The paper itself

Abstract

purposeTo determine the efficacy and safety of target volume determination by

methodsWe prospectively treated 10 consecutive consenting patients with HNSCC using IMRT, with target volumes determined by PET-CT. Gross tumor volume (GTV) and clinical target volume (CTV) at the oral level were determined by two radiation oncologists for CT, magnetic resonance imaging (MRI), and PET-CT. Differences in target volume (GTV

resultsThe mean GTV was smallest for GTV

conclusionsThe results suggest that the target volume determined by PET-CT could safely reduce GTV size and interobserver variability in patients with locally advanced HNSCC extending into the oral cavity or oropharynx undergoing IMRT. Trial registration UMIN, UMIN000033007. Registered 16 jun 2018, https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037631.

Indexed as

18F-FDGDental artifactsHead and neck cancerIntensity-modulated radiation therapyInterobserver variabilityOral cavityOropharynxPET-CTTarget delineation

Identifiers

PMID38748042
PMCPMC10962625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.